Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
Rajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-03-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/metabolic-profiling-of-follistatin-overexpression-a-novel-therapeutic--peer-reviewed-article-DMSO |
id |
doaj-205fa0d3ae934c8c9884377911147ff2 |
---|---|
record_format |
Article |
spelling |
doaj-205fa0d3ae934c8c9884377911147ff22020-11-25T00:29:59ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity : Targets and Therapy1178-70072018-03-01Volume 11658437419Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseasesSingh RPervin SLee SKuo AGrijalva VDavid JVergnes LReddy STRajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; 3The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; 4Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, CT, USA; 5Department of Biology, California State University Dominguez Hills, CA, USA; 6Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA, USA; 7Department of Comparative Medicine, Pfizer Inc, San Diego, CA, USA; 8Department of Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA Background: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues.Methods: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type (WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics (gas chromatography) was analyzed in 3T3-L1 cells.Results: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clearance, improved plasma lipid profiles and significant changes in several conventional metabolites compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up regulation of key brown/beige markers and changes in lipidomics profiles. Conclusion: Fst modulates key factors involved in promoting metabolic syndrome and could be used for therapeutic intervention. Keywords: follistatin, transgenic, adipocyte, fibroblast growth factor 21, AdipoQhttps://www.dovepress.com/metabolic-profiling-of-follistatin-overexpression-a-novel-therapeutic--peer-reviewed-article-DMSOFollistatinBrowningObesityMetabolic profilingMetabolic Diseases |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Singh R Pervin S Lee S Kuo A Grijalva V David J Vergnes L Reddy ST |
spellingShingle |
Singh R Pervin S Lee S Kuo A Grijalva V David J Vergnes L Reddy ST Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy Follistatin Browning Obesity Metabolic profiling Metabolic Diseases |
author_facet |
Singh R Pervin S Lee S Kuo A Grijalva V David J Vergnes L Reddy ST |
author_sort |
Singh R |
title |
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases |
title_short |
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases |
title_full |
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases |
title_fullStr |
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases |
title_full_unstemmed |
Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases |
title_sort |
metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases |
publisher |
Dove Medical Press |
series |
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
issn |
1178-7007 |
publishDate |
2018-03-01 |
description |
Rajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; 3The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; 4Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, CT, USA; 5Department of Biology, California State University Dominguez Hills, CA, USA; 6Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA, USA; 7Department of Comparative Medicine, Pfizer Inc, San Diego, CA, USA; 8Department of Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA Background: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues.Methods: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type (WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics (gas chromatography) was analyzed in 3T3-L1 cells.Results: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clearance, improved plasma lipid profiles and significant changes in several conventional metabolites compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up regulation of key brown/beige markers and changes in lipidomics profiles. Conclusion: Fst modulates key factors involved in promoting metabolic syndrome and could be used for therapeutic intervention. Keywords: follistatin, transgenic, adipocyte, fibroblast growth factor 21, AdipoQ |
topic |
Follistatin Browning Obesity Metabolic profiling Metabolic Diseases |
url |
https://www.dovepress.com/metabolic-profiling-of-follistatin-overexpression-a-novel-therapeutic--peer-reviewed-article-DMSO |
work_keys_str_mv |
AT singhr metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT pervins metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT lees metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT kuoa metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT grijalvav metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT davidj metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT vergnesl metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT reddyst metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases |
_version_ |
1725328621556465664 |